JVM Co

JVM Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of JVM Co (054950.KQ) as of Nov 3, 2026 is 89.99 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.17 % — a change of 16.61% (higher).

FCF Conversion

89.99 %

YoY

16.61%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of JVM Co is 2025 89.99 % . FCF Conversion Rate (FCF/EBITDA) of JVM Co was 2024 77.17 % . It decreases by 16.61% higher compared to the previous year.

The JVM Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
189.51 KRW
Jan 1, 2019
238.12 KRW
Jan 1, 2020
121.35 KRW
Jan 1, 2021
234.21 KRW
Jan 1, 2022
63.84 KRW
Jan 1, 2023
101.51 KRW
Jan 1, 2024
77.17 KRW
Jan 1, 2025
89.99 KRW
The JVM Co FCF Conversion history
YEARFCF ConversionYoY
89.99 %+16.61%
77.17 %-23.98%
101.51 %+59.01%
63.84 %-72.74%
234.21 %+93.00%
121.35 %-49.04%
238.12 %+25.65%
189.51 %+85.24%
102.31 %+72.31%
59.37 %-50.60%
120.18 %-25.21%
160.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JVM Co Stock analysis

What does JVM Co do? JVM Co., Ltd. manufactures pharmacy automation systems under the brand JVM, targeting domestic and overseas markets. The company's primary products include automatic tablet dispensing and packaging systems (ATDPSs), automatic tablet classification and packing machines available in slide, box, and drum types, total safety solutions, automatic medication vision inspection systems (VIZENs), automatic package cutting and winding systems (WIZERs), and automatic medication sorting and control systems (AccuPharm). These products are sold to customers in the pharmaceutical and healthcare sectors seeking efficient automation solutions for medication handling and safety. The firm generates revenue through the sale of its branded automation systems, with a focus on domestic distribution and international markets. JVM's product portfolio addresses key operational needs in pharmacy settings, including dispensing, classification, inspection, and sorting of medications, ensuring compliance with safety standards while improving workflow efficiency. The company's offerings are designed to meet the demands of healthcare providers and pharmaceutical manufacturers requiring advanced automation technologies. JVM's business model centers on providing comprehensive automation solutions for pharmacy operations, leveraging its established brand JVM to differentiate its products in the market. By offering a wide range of specialized systems, the company caters to both domestic and international clients seeking reliable, high-quality automation equipment for medication management and safety protocols. JVM Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JVM Co stock

FCF Conversion Rate (FCF/EBITDA) of JVM Co is 89.99 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of JVM Co changed from 77.17 % to 89.99 %, representing a 16.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) JVM Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s JVM Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — JVM Co

All Key Metrics — JVM Co